Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

A strategy to investigate cell type-specific effects of non-coding regulatory elements to be applied in neurodegeneration research

NOJUNKDNA

I here propose a strategy to investigate cell type-specific effects of non-coding regulatory elements, which have been shown to play a fundamental role during the molecular pathophysiology of complex neurodegenerative diseases such as glaucoma in the eye or Alzheimer's or Parkinson's in the brain. By leveraging techniques from various scientific...

Funding Programme
Start Date
End Date
Total Funding
€ 171 461
European Countries Involved

ADAMtx: Development of Alzheimer’s immunotherapy by harnessing the natural reparative properties of microglia

ADAMtx

Alzheimer's disease (AD) is a heterogeneous disease in which multiple detrimental factors contribute to cognitive loss and disease escalation. Currently there are no effective therapies for AD. Targeting any single symptom of disease-escalating factor (e.g. amyloid beta, tau, neuroinflammation etc.), even if successful, is not sufficient to modify...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Advancing the non-invasive assessment of brain communication in neurological disease

TrueBrainConnect

Pathological communication between different brain regions has been implicated in various neurological disorders. However, the computational tools for assessing such communication from neuroimaging data are not sufficiently developed. The goal of TrueBrainConnect is to establish brain connectivity analysis using non-invasive electrophysiology as a...

Funding Programme
Start Date
End Date
Total Funding
€ 1 499 875
European Countries Involved

affecTive basEd iNtegrateD carE for betteR Quality of Life

TeNDER

With an increasingly growing population in Europe, cognitive impairments as well as heart diseases are a major social and health issue. 1.2 million people in Europe are affected by Parkinson's disease (PD) while Alzheimer’s disease remains one of the biggest global public health challenges our generation is facing, while Cardiovascular disease...

Funding Programme
Start Date
End Date
Total Funding
€ 5 698 333
European Countries Involved

Age-dependent mechanisms of sporadic Alzheimer’s Disease in patient-derived neurons

AGEMEC

Sporadic Alzheimer’s Disease (AD) accounts for the overwhelming majority of all AD cases and exclusively affects people at old age. However, mechanistic links between aging and AD pathology remain elusive. We recently discovered that in contrast to iPSC models, direct conversion of human fibroblasts into induced neurons (iNs) preserves signatures...

Funding Programme
Start Date
End Date
Total Funding
€ 1 499 565
European Countries Involved

Alzheimer Disease - gut connection

AD-gut

Alzheimer’s disease (AD) is the leading cause of dementia in the Western world and to date no cure nor any preventive strategy are available for this neurodegenerative disorder. Bacterial 16S rRNA sequencing from fecal samples revealed a remarkable shift in the gut microbiota of conventionally-raised AD mice compared to healthy, wild-type mice...

Funding Programme
Start Date
End Date
Total Funding
€ 7 686 620
European Countries Involved

Alzheimer's Disease (AD) Detect & Prevent - Presymptomatic AD detection and prevention

AD Detect-Prevent

Alzheimer’s disease (AD) is central to the rapidly growing and crushing ageing challenge that threatens to economically undermine today’s health care system. AD prevalence will grow to over 100m cases in 2050. AD is incurable, but can be prevented. Detecting pre-symptomatic signs of AD in at-risk groups and intervening early may be the only viable...

Funding Programme
Start Date
End Date
Total Funding
€ 3 880 990
European Countries Involved

Alzheimer's disease and Zinc: the missing link ?

aLzINK

Alzheimer's disease (AD) is one of the most serious diseases mankind is now facing as its social and economical impacts are increasing fastly. AD is very complex and the amyloid-β (Aβ) peptide as well as metallic ions (mainly copper and zinc) have been linked to its aetiology. While the deleterious impact of Cu is widely acknowledged, intervention...

Funding Programme
Start Date
End Date
Total Funding
€ 1 499 948
European Countries Involved

AlzheimersInAction: A multi-disciplinary approach to determine the cellular and molecular mechanisms underlying the inflammatory response to amyloid-β in Alzheimer’s disease.

AlzheimersInAction

In addition to devastation for the patients and their families, Alzheimer’s disease (AD) generates enormous costs for the wider European economy and is an urgent health priority. There are currently no drug treatments that can cure AD or other common forms of dementia. This absence of therapeutic interventions comes from a lack of understanding...

Funding Programme
Start Date
End Date
Total Funding
€ 224 934
European Countries Involved

Alzheimer’s disease and AAV9: Use of a virus-based delivery system for vectored immunoprophylaxis in dementia.

AD-VIP

Alzheimer’s disease (AD) is the most common form of dementia in the Western World, representing an economic and social cost of billions of euros a year. Given the changing demographics of society, these costs will only increase over the coming decades.Amyloid plaques, composed of amyloid beta peptide (Abeta), are a defining characteristic of AD...

Funding Programme
Start Date
End Date
Total Funding
€ 150 000
European Countries Involved

Alzheimer’s Disease Diagnosis by Spectroscopy. Accurate and Non-Invasive Medical Device for the Diagnosis of Early Stage Alzheimer's Disease.

ADiRaS

Raman HT is a company expert on Raman Spectroscopy (RS) which has developed a revolutionary medical device to diagnose Alzheimer’s Disease (AD) in blood plasma for the first time. Currently, there are only two accurate methods to diagnose AD, expensive, invasive with multiple side effects. Positron Emission Tomography (PET) scans the patient’s...

Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

An embodied perspective on anosognosia

VirtualSync

In addition to impairments in episodic and spatial memory, a lack of awareness for one’s memory deficits (also referred to as anosognosia) may be considered a crucial cognitive marker of Alzheimer’s Disease (AD). However, although a growing body of interesting models have been proposed to explain this early symptom, what is still missing is a...

Funding Programme
Start Date
End Date
Total Funding
€ 175 420
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).